ahlam1399
06-27-2016, 11:36 AM
Allergy Therapeutics says study fails to find hay fever therapy dose range
June 27 (Reuters) - Drug developer Allergy Therapeutics Plc said a study on suitable doses of its therapy to treatgrass allergic rhinitis, or hay fever, did **t find arecommended dose for a late-stage trial.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=4vRRMzhhook:pA3h90M3IhE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4vRRMzhhook:pA3h90M3IhE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=4vRRMzhhook:pA3h90M3IhE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4vRRMzhhook:pA3h90M3IhE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=4vRRMzhhook:pA3h90M3IhE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/4vRRMzhhook
June 27 (Reuters) - Drug developer Allergy Therapeutics Plc said a study on suitable doses of its therapy to treatgrass allergic rhinitis, or hay fever, did **t find arecommended dose for a late-stage trial.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=4vRRMzhhook:pA3h90M3IhE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4vRRMzhhook:pA3h90M3IhE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=4vRRMzhhook:pA3h90M3IhE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4vRRMzhhook:pA3h90M3IhE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=4vRRMzhhook:pA3h90M3IhE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/4vRRMzhhook